Antibodies for therapeutic uses and the evolution of biotechniques

Current Medicinal Chemistry

Volumn 16, Issue 6, 2009, Pages 753-779

  Nieri, P ^a   Donadio, E ^a   Rossi, S ^a   Adinolfi, B ^a   Podesta A ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Catalytic antibodies; Delivering antibodies; Intracellular antibodies; Neutralizing blocking antibodies; Production strategies; Signaling antibodies; Therapeutic antibodies

Indexed keywords

ABCIXIMAB; ADALIMUMAB; ALEMTUZUMAB; ANTERGREN; BASILIXIMAB; BEVACIZUMAB; CERTOLIZUMAB PEGOL; CETUXIMAB; DACLIZUMAB; ECULIZUMAB; EDRECOLOMAB; EFALIZUMAB; GEMTUZUMAB OZOGAMICIN; IBRITUMOMAB TIUXETAN; IMMUNOGLOBULIN FC FRAGMENT; INFLIXIMAB; IPILIMUMAB; NATALIZUMAB; NIMOTUZUMAB; OKT 3; OMALIZUMAB; PALIVIZUMAB; PANITUMUMAB; RANIBIZUMAB; RECOMBINANT ANTIBODY; RITUXIMAB; SEVIRUMAB; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TOSITUMOMAB I 131; TRASTUZUMAB; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ANKYLOSING SPONDYLITIS; ANTIGEN ANTIBODY COMPLEX; ANTIGEN ANTIBODY REACTION; ANTIGEN BINDING; ANTIGEN RECOGNITION; ASTHMA; B CELL LEUKEMIA; BINDING AFFINITY; BIOTECHNOLOGY; BREAST CANCER; CARDIAC GRAFT REJECTION; CATALYSIS; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATORIAL CHEMISTRY; CROHN DISEASE; CRYSTAL STRUCTURE; DIMERIZATION; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG EFFECT; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; DRUG RESPONSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TARGETING; GRAFT REJECTION; HEAD AND NECK CANCER; HEAD AND NECK CARCINOMA; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; KIDNEY GRAFT REJECTION; LIVER GRAFT REJECTION; LOWER RESPIRATORY TRACT INFECTION; LUNG NON SMALL CELL CANCER; LYMPHOCYTOPENIA; MELANOMA; MULTIPLE SCLEROSIS; NEUTROPENIA; NONHODGKIN LYMPHOMA; NONHUMAN; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PROTEIN GLYCOSYLATION; PSORIASIS; PSORIATIC ARTHRITIS; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; RETINA MACULA AGE RELATED DEGENERATION; REVIEW; RHEUMATOID ARTHRITIS; SQUAMOUS CELL CARCINOMA; THROMBOSIS; ULCERATIVE COLITIS; VIRUS INFECTION;

ANTIBODIES; ANTIBODIES, MONOCLONAL; BIOTECHNOLOGY; HUMANS;

EID: 65649104119     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787458380     Document Type: Review

References (311)

1. Newcombe, C.; Newcombe, A.R. Antibody production: Polyclonal-derived biotherapeutics. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci., 2007, 848, 2-7.
2. Ashkenazi, A.; Chamow, S.M. Immunoadhesins as research tools and therapeutic agents. Curr. Opin. Immunol., 1997, 9, 195-200.
3. Feldmann, M.; Maini, S.R. Role of cytokines in rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol. Rev., 2008, 223, 7-19.
4. Deonarain, M.P. Recombinant antibodies for cancer therapy. Exp. Opin., 2008, 8, 1123-41.
5. Wang, S.Y.; Weiner, G. Complement and cellular cytotoxicity in antibody therapy of cancer. Exp. Opin. Biol. Ther., 2008, 8, 759-68.
6. Jefferis R. Antibody therapeutics: Isotype and glycoform selection. Expert Opin. Biol. Ther., 2007, 7, 1401-13.
7. Presta, L.G. Engineering antibodies for therapy. Curr. Pharm. Biotechnol., 2002, 3, 237-56.
8. Olafsen, T.; Kenanova, V.E.; Wu, A.M. Tunable pharmacokinetics: modifying the in vivo half-life of antibodies by directed mutagenesis of the Fc fragment. Nat. Protoc., 2006, 1, 2048-60.
9. Ternant, D.; Paintaud, G. Pharmacokinetics and concentration-effect relationships of therapeutic monoclonal antibodies and fusion proteins. Expert Opin. Biol. Ther., 2005, 5, S37-S47
10. Morrison, S.L.; Johnson, M.J.; Herzenberg, L.A.; Oi, V.T. Chimeric human antibody molecules; mouse antigen-binding domains with human constant region domains. Proc. Natl. Acad. Sci. USA, 1984, 21, 6851-5.
11. Bell, M.; Kamm, M. The clinical role of anti-TNFα antibody treatment in Crohn's disease. Aliment. Phamacol. Ther., 2000, 14, 501-14.
12. Miele, E.; Markowitz, J.E.; Mamula, P.; Baldassano, R.N. Human antichimeric antibody in children and young adults with inflammatory bowel disease receiving infliximab. J. Pediatr. Gastroenterol. Nutr., 2004, 38, 502-8.
13. Jones, P.T.; Dear, P.H.; Foote, J.; Neuberger, M.S.; Winter, G. Replacing the complementarity-determining regions in a human antibody with those from a mouse. Nature, 1996, 321, 522-5
14. Presta, L.G. Engineering of therapeutic antibodies to minimize immunogenicity and optimize function. Adv. Drug Deliv. Rev. 2006, 58, 640-56.
15. Tsurushita, N.; Hinton, P.R.; Kumar, S. Design of humanized antibodies: from anti-Tac to Zenapax. Methods, 2005, 36, 69-83.
16. Hwang, W.Y.K.; Almagro, J.C.; Buss, T.N.; Tan, P.; Foote, J. Use of human germline genes in a CDR homology-based approach to antibody humanization. Methods, 2005, 36, 35-42.
17. Dall'Acqua, W.F.; Damschroder, M.M.; Zhang, J.; Woods, R.M.; Widjaja, L.; Yu, J.; Wu, H. Antibody humanization by framework shuffling. Methods, 2005, 36, 43-60.
18. Kashmiri, S.V.; De Pascalis, R.; Gonzales, N.R.; Schlom, J. SDR grafting-a new approach to antibody humanization. Methods, 2005, 36, 25-34.
19. source IMGT repertoire website: http://imgt.cines.fr/textes/ IMGTrepertoire/GenesClinical/monoclonalantibodies/ #Human_monoclonal∠tibodies).
20. Köhler, G; Milstein, C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature, 1975, 256, 495-7.
21. Nissim, A.; Chernajovsky, Y. Historical development of monoclonal antibody therapeutics. Handb. Exp. Pharmacol., 2008, 181, 3-18.
22. Bruggemann, M.; Taussig, M.J. Production of human antibody repertoires in transgenic mice. Curr. Opin. Biotechnol., 1997, 8, 455-8.
23. Fishwild, D.M.; O'Donnell, S.L.; Bengoechea, T.; Hudson, D.V.; Harding, F. Bernhard, S.L.; Jones, D.; Kay, R.M.; Higgins, K.M.; Schramm, S.R.; Lonberg, N. High-avidity human IgG kappa monoclonal antibodies from a novel strain of minilocus transgenic mice. Nat. Biotechnol., 1996, 14, 845-51.
24. Mendez, M.; Green, L.; Corvalan, J.; Jia, X.C.; Maynard-Currie, C.; Yang, X.D.; Gallo, M.L.; Louie, D.M.; Lee, D.V.; Erickson, K.L.; Luna, J.; Roy, C.M.; Abderrahim, H.; Kirschenbaum, F.; Noguchi, M.; Smith, D.H.; Fukushima, A.; Hales, J.F.; Klapholz, S.; Finer, M.H.; Davis, C.G.; Zsebo, K.M.; Jakobovits, A. Functional transplant of megabase human immunoglobulin loci recapitulates human antibody response in mice. Nat. Genet., 1997, 15, 146-56.
25. Yang, X.D.; Corvalan, J.R.; Wang, P.; Roy, C.M.; Davis, C.G. Fully human antiinterleukin-8 monoclonal antibodies: Potential therapeutics for the treatment of inflammatory disease states. J. Leukocyte Biol., l999, 66, 401-10.
26. Yang, X.D.; Jia, X.C.; Corvalan, J.R.; Wang, P.; Davis, C.G.; Jakobovits, A. Eradication of established tumors by a fully human monoclonal antibody to the epidermal growth factor receptor without concomitant chemotherapy. Cancer Res., 1999, 59, 1236-43.
27. Lonberg, N. Human antibodies from transgenic animals. Nat. Biotechnol., 2005, 23, 1117-25.
28. Yang, W.P.; Green, K.; Pinz-Sweeney, S.; Briones, A.T.; Burton, D.R., Barbas, C.F. 3rd. CDR walIking mutagenesis for the affinity maturation of a potent human anti-HIV-1 antibody into the picomolar range. J. Mol. Biol., 1995, 254, 392-403.
29. Graddis, T.J; Remmele, R.L. Jr; McGrew, J.T. Designing proteins that work using recombinant technologies. Curr. Pharm. Biotechnol., 2002, 3, 285-97.
30. Raju, T.S. Terminal sugars of Fc glycans influence antibody effector functions of IgGs. Curr. Opin. Immunol., 2008, 20, 471-8.
31. Wright, A.; Morrison, S.L. Effect of glycosylation on antibody function: implications for genetic engineering. Trends Biotechnol., 1997, 15, 26-32.
32. Strome, S.E.; Sausville, E,A; Mann, D. A. mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. Oncologist, 2007, 12, 1084-95.
33. Leibiger, H.; Wustner, D.; Stigler, R.D.; Marx, U. Variable domain-linked oligosaccharides of a human monoclonal IgG: Structure and influence on antigen binding. Biochem. J., 1999, 338, 529-38.
34. Kim, H.; Yamaguchi, Y.; Masuda, K.; Matsunaga, C.; Yamamoto, K.; Irimura, T.; Takahashi, N.; Kato, K.; Arata, Y. O-glycosylation in hinge region of mouse immunoglobulin G2b. J. Biol. Chem., 1994, 269, 12345-50.
35. Tao, M.H.; Morrison, S.L. Studies of aglycosylated chimeric mouse-human IgG: Role of carbohydrate in the structure and effector functions mediated by the human IgG constant region. J. Immunol., 1989, 143, 2595-601.
36. Mattu, T.S.; Pleass, R.J.; Willis, A.C.; Kilian, M.; Wormald, M.R.; Lellouch, A.C.; Rudd, P.M.; Woof, J.M.; Dwek, R.A. The glycosylation and structure of human serum IgA1, Fab, and Fc regions and the role of N-glycosylation on Fc alpha receptor interactions. J. Biol. Chem., 1998, 273, 2260-72.
37. Das, R.C.; Brinkley, S.A.; Heath, E.C. Factors affecting the efficiency of co-translational processing of a de novo synthesized glycosylated immunoglobulin light chain. J. Biol. Chem., 1980, 255, 7933-40.
38. Jefferis, R. Glycosylation of recombinant antibody therapeutics. Biotechnol. Progr., 2005, 21, 11-6.
39. Patel, T.P.; Parekh, R.B.; Moellering, B.J.; Prior, C.P. Different culture methods lead to differences in glycosylation of a murine IgG monoclonal antibody. Biochem. J., 1992, 285, 839-45
40. Ballou, C.E. Isolation, characterization, and properties of Saccharomyces cerevisiae mnn mutants with nonconditional protein glycosylation defects. Methods Enzymol., 1990, 185, 440-70.
41. Cabanes-Macheteau, M.; Fitchette-Lainé, A.C.; Loutelier-Bourhis, C.; Lange, C.; Vine, N.D.; Ma, J.K.; Lerouge, P.; Faye, L. N-Glycosylation of a mouse IgG expressed in transgenic tobacco plants. Glycobiology, 1999, 9, 365-72.
42. Noguchi, A.; Mukuria, C.J.; Suzuki, E.; Naiki, M. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J. Biochem., 1995, 117, 59-62.
43. Borrebaeck, C.K.; Malmborg, A.C.; Ohlin, M. Does endogenous glycosylation prevent the use of mouse monoclonal antibodies as cancer therapeutics? Immunol. Today, 1993, 14, 477-9.
44. Varki, A. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology, 1993, 3, 97-130.
45. Wilson, I.B.; Gavel, Y.; von Heijne, G. Amino acid distributions around O-linked glycosylation sites. Biochem. J., 1991, 275, 529-34.
46. Delin, Z.; McCarthy, H.; Christian, H.; Johnson, O.P.; Hamblin, T.J.; Stevenson, F.K. Acquisition of potential N-glycosylation sites in the immunoglobulin variable region by somatic mutation is a distinctive feature of follicular lymphoma. Blood, 2002, 99, 2562-8.
47. Kabat, E.; Sequences of proteins of immunological interest. Bethesda, MD: US Department of Health and Human services, Public Health Services, National Institutes of Health; 1991. Publication 91-3242, 3.
48. Coloma, M.J.; Trinh, R.K.; Martinez, A.R.; Morrison, S.L. Position effects of variable region carbohydrate on the affinity and in vivo behavior of an anti-(136) dextran antibody. J. Immunol. 1999, 162, 2162-70.
49. Zelenetz, A.D.; Chen, T.T.; Levy, R. Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell. J. Exp. Med., 1991, 173, 197-207.
50. Crocker, P.R.; Feizi, T. Carbohydrate recognition systems: Functional triads in cell-cell interactions. Curr. Opin. Struct. Biol., 1996, 6, 679-91.
51. Wallick, S.C.; Kabat, E.A.; Morrison, S.L. Glycosylation of a VH residue of a monoclonal antibody against alpha (136) dextran increases its affinity for antigen. J. Exp. Med., 1988, 168, 1099-109.
52. Fujimura, Y.; Tachibana, H.; Eto, N.; Yamada, K. Antigen binding of an ovomucoid-specific antibody is affected by a carbohydrate chain located on the light chain variable region. Biosci. Biotechnol. Biochem., 2000, 64, 2298-305.
53. Middaugh, C.R.; Litman, G.W. Atypical glycosylation of an IgG monoclonal cryoimmunoglobulin. J. Biol. Chem., 1987, 262, 3671-3.
54. Iida, S.; Misaka, H.; Inoue, M.; Shibata, M.; Nakano, R.; Yamane-Ohnuki, N.; Wakitani, M.; Yano, K.; Shitara, K.; Satoh, M. Nonfucosylated therapeutic IgG1 antibody can evade the inhibitory effect of serum immunoglobulin G on antibody-dependent cellular cytotoxicity through its high binding to FcgammaRIIIa. Clin. Cancer Res., 2006, 12, 2879-87.
55. Suzuki, E.; Niwa, R.; Saji, S.; Muta, M.; Hirose, M.; Iida, S.; Shiotsu, Y.; Satoh, M.; Shitara, K.; Kondo, M.; Toi, M. A nonfucosylated anti-HER2 antibody augments antibody-dependent cellular cytotoxicity in breast cancer patients. Clin. Cancer Res., 2007, 13, 1875-82.
56. Satoh, M.; Iida, S.; Shitara, K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther., 2006, 6, 1161-73.
57. Ko, K.; Ahn, M.H.; Song, M.; Choo, Y.K.; Kim, H.S.; Ko, K.; Joung, H. Glyco-engineering of biotherapeutic proteins in plants. Mol. Cells, 2008, 25, 494-503.
58. Shi, X.; Jarvis, D. L. Protein N-glycosylation in the baculovirus-insect cell system. Curr. Drug Targets, 2007, 8, 1116-25
59. Hamilton, S.R.; Gerngross, T.U. Glycosylation engineering in yeast: The advent of fully humanized yeast. Curr. Opin. Biotechnol. 2007, 18, 387-92.
60. Chiba, Y.; Jigami, Y. Production of humanized glycoproteins in bacteria and yeasts. Curr. Opin. Chem. Biol., 2007, 11, 670-6.
61. Morrow, K.J. Jr. Advances in antibody manufacturing using mammalian cells. Biotechnol. Annu. Rev., 2007, 13, 95-113.
62. Werner, R.G.; Kopp, K.; Schlueter, M. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr. Suppl., 2007, 96, 17-22.
63. Salas, J.A.; Méndez, C. Engineering the glycosylation of natural products in actinomycetes. Trends Microbiol., 2007, 15, 219-32.
64. Chang, C.H.; Sharkey, R.M.; Rossi, E.A.; Karacay, H.; McBride, W.; Hansen, H.J.; Chatal, J.F.; Barbet, J.; Goldenberg, D.M. Molecular advances in pretargeting radioimunotherapy with bispecific antibodies. Mol. Cancer Ther., 2002, 1, 553-63.
65. Colcher, D.; Pavlinkova, G.; Beresford, G.; Booth, B.J.; Choudhury, A.; Batra, S.K. Pharmacokinetics and biodistribution of genetically-engineered antibodies. Q. J. Nucl. Med., 1998, 42, 225-41.
66. Wu, A.M.; Yazaki, P.J. Designer genes: Recombinant antibody fragments for biological imaging. Q. J. Nucl. Med., 2000, 44, 268-83.
67. Wu, A.M. Engineering multivalent antibody fragments for in vivo targeting. Methods Mol. Biol., 2004, 248, 209-25.
68. Pluckthun, A. In Handbook of experimental pharmacology; Martin Rosenberg; Gordon P. Moore, Eds.; Springer-Verlag: Berlin, 1994; Vol. 3, pp. 269-315.
69. Huston, J.S.; McCartney, J.; Tai, M.S.; Mottola, H.C.; Jin, D.; Warren, F.; Keck, P.; Oppermann, H. Medical applications of single-chain antibodies. Int. Rev. Immunol., 1993, 10, 195-217
70. Raag, R.; Whitlow, M. Single-chain Fvs. FASEB J., 1995, 9, 73-80.
71. Ward, E.S.; Gussow, D.; Griffiths, A.D.; Jones, P.T.; Winter, G. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature, 1989, 341, 544-6.
72. Holt, L.J.; Herring, C.; Jespers, L.S.; Woolven B.P.; Tomlinson, I.M. Domain antibodies: Proteins for therapy. Trends Biotechnol., 2003, 21, 484-90.
73. Pant, N.; Hultberg, A.; Zhao, Y.; Svensson, L.; Pan-Hammarstrom, Q.; Johansen, K.; Pouwels, P.H.; Ruggeri, F.M.; Hermans, P.; Frenken, L.; Borén, T.; Marcotte, H.; Hammarström, L. Lactobacilli expressing variable domain of llama heavy-chain antibody fragments (lactobodies) confer protection against rotavirus-induced diarrhea. J. Infect. Dis., 2006, 194, 1580-8.
74. Bird, R.E.; Hardman, K.D.; Jacobson, J.W.; Johnson, S.; Kaufman, B.M.; Lee, S.M.; Lee, T.; Pope, S.H.; Riordan, G.S.; Whitlow, M. Single-chain antigen-binding proteins. Science, 1988, 242, 423-6
75. Brinkmann, U.; Reiter, Y.; Jung, S.H.; Lee, B.; Pastan, L. A recombinant immunotoxin containing a disulfide-stabilized Fv fragment. Proc. Natl. Acad. Sci. USA, 1993, 90, 7538-42.
76. Holliger, P.; Prospero, T.; Winter, G. 'Diabodies': Small bivalent and bispecific antibody fragments. Proc. Natl. Acad. Sci. USA, 1993, 90, 6444-8.
77. Santimaria, M.; Moscatelli, G.; Viale, G.L.; Giovannoni, L.; Neri, G.; Viti, F.; Leporini, A.; Borsi, L.; Castellani, P.; Zardi, L.; Neri, D.; Riva, P. lmmunoscintigraphic detection of the ED-B domain of fibronectin, a marker of angiogenesis, in patients with cancer. Clin. Cancer Res., 2003, 9, 571-9.
78. Kriangkum, J.; Xu, B.; Nagata, L.P.; Fulton, R.E.; Suresh M.R. Bispecific and bifunctional single chain recombinant antibodies. Biomol. Eng., 2001, 18, 31-40.
79. Alt, M.; Muller, R.; Kontermann, R.E. Novel tetravalent and bispecific IgG-like antibody molecules combining single chain diabodies with the immunoglobulin gamma1 Fc or CH3 region. FEBS Lett., 1999, 454, 90-4.
80. Bera, T.K.; Onda, M.; Brinkmann, U.; Pastan, L. A bivalent disulfide-stabilized fv with improved antigen binding to erbB2. J. Mol. Biol., 1998, 281, 475-83.
81. Hu, S.; Shively, L.; Raubitschek, A.; Sherman, M.; Williams, L.E.; Wong, J.Y.C.; Shively, J.E.; Wu, A.M. Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts. Cancer Res., 1996, 56, 3055-61.
82. Klemm, J.D.; Schreiber, S.L.; Crabtree, G.R. Dimerization as a regulatory mechanism in signal transduction. Annu. Rev. Immunol., 1998, 16, 569-92.
83. Clynes, R.A.; Towers, T.L.; Presta, L.G.; Ravetch, J.V. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets. Nat. Med., 2000, 6, 443-6.
84. Di Fiore, P.P.; Gill, G.N. Endocytosis and mitogenic signaling. Curr. Opin. Cell Biol., 1999, 11, 483-8.
85. Ghetie, M.; Podar, E.M.; Ilgen, A.; Gordon, B.E.; Uhr, J.W.; Vitetta, E.S. Homodimerization of tumor-reactive monoclonal antibodies markedly increases their ability to induce growth arrest or apoptosis of tumor cells. Proc. Natl. Acad. Sci. USA, 1997, 94, 7509-14.
86. Ghetie, M.A.; Bright, H.; Vitetta, E.S. Homodimers but not monomers of Rituxan (chimeric anti-CD20) induce apoptosis in human B-lymphoma cells and synergize with a chemotherapeutic agent and an immunotoxin. Blood, 2001, 97, 1392-8.
87. Zhao, Y.; Kohler, H. Enhancing tumor targeting and apoptosis using noncovalent antibody homodimers. J. Immunother., 2002, 25, 396-404.
88. Tutt, A.; Stevenson, G.T.; Glennie, M.J. Trispecific F(ab')3 derivatives that use cooperative signaling via the TCR/CD3 complex and CD2 to activate and redirect resting cytotoxic T cells. J. Immunol., 1991, 17, 60-9.
89. Kan, K.S.; Anderson, V.A.; Leong, W.S.; Smith, A.M.; Worth, A.T.; Stevenson, G.T. Thioether-bonded constructs of Fab'γ and Fcγ modules utilizing differential reduction of interchain disulfide bonds. J. Immunol., 2001, 166, 1320-6.
90. Olafsen, T.; Rasmussen, I.B.; Norderhaug, L.; Bruland, O.S.; Sandlie, I. IgM secretory tailpiece drives multimerisation of bivalent scFv fragments in eukaryotic cells. Immunotechnology, 1998, 4, 141-53.
91. Choi, I.; Schmitt, W.E.; Bahre, A.; Little, M.; Cochlovius, B. Recombinant chimeric OKT3/IgM antibodies for immune suppression: evaluation in a human CD3 transgenic mouse model. Immunol. Lett., 2002, 80, 125-8.
92. Smith, R.I.F.; Coloma, M.J.; Morrison, S.L. Addition of a μ-tailpiece to IgG results in polymeric antibodies with enhanced effector functions including complement-mediated cytolysis by IgG4. J. Immunol., 1995, 154, 2226-36.
93. Kipriyanov, S.M.; Breitling, F.; Little, M.; Dübel, S. Single-chain antibody streptavidin fusions: Tetrameric bifunctional scFv-complexes with biotinbinding activity and enhanced affinity to antigen. Hum. Antibod. Hybridomas, 1995, 6, 93-101.
94. Coloma, M.J.; Morrison S.L. Design and production of novel tetravalent bispecific antibodies. Nat. Biotechnol., 1997, 15, 159-63.
95. Zapata, G.; Ridgway, J.B.; Mordenti, J.; Osaka, G.; Wong, W.L.; Bennett, G.L.; Carter, P. Engineering linear F(ab')2 fragments for efficient production in Escherichia coli and enhanced antiproliferative activity. Protein Eng., 1995, 8, 1057-62.
96. Miller, K.; Meng, G.; Liu, J.; Hurst, A.; Hsei, V.; Wong, W.L.; Ekert, R.; Lawrence, D.; Sherwood, S.; DeForge, L.; Gaudreault, J.; Keller, G.; Sliwkowski, M.; Ashkenazi, A.; Presta, L. Design, Construction, and in vitro analyses of multivalent antibodies. J. Immunol., 2003, 170, 4854-61.
97. Todorovska, A.; Roovers, R.C.; Dolezsal, O.; Kortt, A.A.; Hoogenboom, H.R.; Hudson, P.J. Design and application of diabodies, triabodies and tetrabodies for cancer targeting. J. Immunol. Methods, 2001, 248, 47-66.
98. Willuda, J.; Kubetzko, S.; Waibel, R.; Schubiger, P.A.; Zangemeister-Wittke, U.; Pluckthun, A. Tumor targeting of mono-, di-, and tetravalent antip185HER-2 miniantibodies multimerized by self-associating peptides. J. Biol. Chem., 2001, 276, 14385-92.
99. Kujau, M.J.; Hoischen, C.; Riesenberg, D.; Gumpert, J. Expression and secretion of functional miniantibodies McPC603scFvDhlx in cell-wall-less L-form strains of Proteus mirabilis and Escherichia coli: A comparison of the synthesis capacities of L-form strains with an E. coli producer strain. Appl. Microbiol. Biotechnol., 1998, 49, 51-8.
100. Pack, P.; Plückthun, A. Miniantibodies: Use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. Biochemistry, 1992, 31, 1579-84.
101. Pack, P.; Kujau, M.; Schroeckh, V.; Knüpfer, U.; Wenderoth, R.; Riesenberg, D.; Plückthun, A. Improved bivalent miniantibodies, with identical avidity as whole antibodies, produced by high cell density fermentation of Escherichia coli. Biotechnology (N Y), 1993, 11, 1271-7.
102. Pack, P.; Muller, K.; Zahn, R.; Plückthun, A. Tetravalent miniantibodies with high avidity assembling in Escherichia coli. J. Mol. Biol., 1995, 246, 28-34.
103. Kostelny, S.A.; Cole, M.S.; Tso, J.Y. Formation of a bispecific antibody by the use of leucine zippers. J. Immunol., 1992, 148, 1547-53.
104. de Kruif, J.; Logtenberg, T. Leucine zipper dimerized bivalent and bispecific scFv antibodies from a semi-synthetic antibody phage display library. J. Biol. Chem., 1996, 271, 7630-4.
105. Neuberger, M.S.; Ehrenstein, M.R.; Klix, N.; Jolly, C.J.; Yélamos, J.; Rada, C.; Milstein, C. Monitoring and interpreting the intrinsic features of somatic hypermutation. Immunol. Rev., 1998, 162, 107-16
106. Wabl, M.; Cascalho, M.; Steinberg, C. Hypermutation in antibody affinity maturation. Curr. Opin. Immunol., 1999, 11, 186-9
107. Raft, M.C. Two distinct populations of peripheral lymphocytes distinguishable by immunofluorescence. Immunology, 1970, 29, 637-50.
108. Rabellino, E.; Colon, S.; Grey, H.M.; Unanue, E.R. Immunoglobulin on the surface of lymphocytes. I. Distribution and quantitation. J. Exp. Med., 1971, 133, 150-67.
109. Bianco, C.; Dukor, P.; Nussenzweig, V. In Morphological and Functional Aspects of Immunity; Kerstin Linkdahl-Kiessling; George Alm; Michael G. Hanna, Jr., Eds.; Plenum Publishing Corporation: New York, 1971; p. 251.
110. Kuby, J. Immunology; Freeman: New York, 1997; pp. 664.
111. Griffiths, A.D.; Duncan, A.R. Strategies for selection of antibodies by phage display. Curr. Opin. Biotechnol., 1998, 9, 102-8.
112. Vaughan, T.J.; Williams, A.J.; Pritchard, K.; Osbourn, J.K.; Pope, A.R.; Earnshaw, J.C.; McCafferty, J.; Hodits, R.A.; Wilton, J.; Johnson, K.S. Human antibodies with subnanomolar affinities isolated from a large non-immunized phage display library. Nat. Biotechnol., 1996, 14, 309-14.
113. Winter, G. Making antibody and peptide ligands by repertoire selection technologies. J. Mol. Recognit., 1998, 11, 126-7.
114. de Kruif, J.; Boel, E.; Logtenberg, T. Selection and application of human single chain Fv antibody fragments from a semi-synthetic phage antibody display library with designed CDR3 regions. J. Mol. Biol., 1995, 248, 97-105.
115. Griffiths, A.D.; Williams, S.C.; Hartley, O.; Tomlinson, L.M.; Waterhouse, P.; Crosbyl, W.L.; Kontermann, R.E.; Jones, P.T.; Low, N.M.; Allison, T.J.; Prospero, T.D.; Hoogenboom, H.R.; Nissim, A.; Coxl, J.P.L.; Harrison, J.L.; Zaccolo, M.; Gherardi, E.; Winter, G. Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J., 1994, 13, 3245-60.
116. Hoogenboom, H.R.; Winter, G. Bypassing immunisation. Human antibodies from synthetic repertoires of germline VH gene segments rearranged in vitro. J. Mol. Biol., 1992, 227, 381-8.
117. Nissim, A.; Hoogenboom, H.R.; Tomlinson, I.M.; Flynn, G.; Midgley, C., Lane, D.; Winter, G. Antibody fragments from a 'single pot' phage display library as immunochemical reagents. EMBO J., 1994, 13, 692-8.
118. Barbas, C.F. 3rd; Bain, J.D.; Hoekstra, O.M.; Lemer, R.A. Semisynthetic combinatorial antibody libraries: A chemical solution to the diversity problem. Proc. Natl. Acad. Sci. USA, 1992, 89, 4457-61.
119. de Wildt, R.M.; Finnern, R.; Ouwehand, W.H.; Griffiths, A.D.; van Venrooij, W.J.; Hoet, R.M. Characterization of human variable domain antibody fragments against the U1 RNA-associated A protein, selected from a synthetic and patient-derived combinatorial V gene library. Eur. J. Immunol., 1996, 26, 629-39.
120. Huls, G.A.; Heijnen, L.A.; Cuomo, M.E.; Koningsberger, J.C.; Wiegman, L.; Boel, E.; van der Vuurst de Vries, A.R.; Loyson, S.A.; Helfrich, W.; van Berge Henegouwen, G.P.; van Meijer, M.; de Kruif, J.; Logtenberg, T. A recombinant, fully human monoclonal antibody with antitumor activity constructed from phagedisplayed antibody fragments. Nat. Biotechnol., 1999, 17, 276-81.
121. Knappik, A.; Ge, L.; Honegger, A.; Pack, P.; Fischer, M.; Wellnhofer, G.; Hoess, A.; Wolle, J.; Pluckthun, A.; Virnekas, B. Fully synthetic human combinatorial antibody libraries (HuCAL) based on modular consensus frameworks and CDRs with randomized trinucleotides. J. Mol. Biol., 2000, 296, 57-86.
122. MRC HGMP Resource Centre for Protein Engineering, Cambridge, UK, reference from: www.hgmp.mrc.ac.uk/geneservice/reagents/products/ descriptions/scFv⊤mlinsonIJ.shtml
123. Boder, E.T.; Wittrup, K.O. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol., 1997, 15, 553-7.
124. Francisco, J.A.; Campbell, R.; Iverson, B.L.; Georgiou, G. Production and fluorescence-activated cell sorting of Escherichia coli expressing a functional antibody fragment on the external surface. Proc. Natl. Acad. Sci. USA, 1993, 90, 10444-8.
125. Fuchs, P.; Breitling, F.; Dubel, S.; Seehaus, T.; Little, M. Targeting recombinant antibodies to the surface of Escherichia coli: Fusion to a peptidoglycan associated lipoprotein. Bio-Technology, 1991, 9, 1369-72.
126. Fuchs, P.; Weichel, W.; Dubel, S.; Breitling, F.; Little, M. Separation of E. coli expressing functional cell-wall bound antibody fragments by FACS. Immunotechnology, 1996, 2, 97-102.
127. Georgiou, G.; Stathopoulos, C.; Daugherty, P.S.; Nayak, A.R.; Iverson, B.L.; Curtiss, R. 3rd. Display of heterologous proteins on the surface of microorganisms: From the screening of combinatorial libraries to live recombinant vaccines. Nat. Biotechnol., 1997, 15, 29-34.
128. Gunneriusson, E.; Samuelson, P.; Uhlen, M.; Nygren, P.A.; Stahl, S. Surface display of a functional single-chain Fv antibody on staphylococci. J. Bacteriol., 1996, 178, 1341-6.
129. Hoogenboom, H.R.; de Bruine, A.P.; Hufton, S.E.; Hoet, R.M.; Arends, J.W.; Roovers R.C. Antibody phage display technology and its applications. Immunotechnology, 1998, 4, 1-20.
130. McCafferty, J.; Griffiths, A.D.; Winter, G.; Chiswell, D.J. Phage antibodies: Filamentous phage displaying antibody variable domain. Nature, 1990, 348, 552-4.
131. Breitling, F.; Dubel, S.; Seehaus, T.; KIeewinghaus, I.; Little, M. Surface expression vector for antibody screening. Gene, 1991, 104, 1047-153.
132. Barbas, C.F. 3rd; Kang, A.S.; Lemer, R.A.; Benkovic, S.J. Assembly of combinatorial antibody libraries on phage surfaces: The gene III site. Proc. Natl. Acad. Sci. USA, 1991, 88, 7987-82.
133. Clackson, T.; Hoogenboom, H.R.; Griffith, A.D.; Winter, G. Making antibody fragments using phage display libraries. Nature, 1991, 352, 624-8.
134. Hoogenboom, H.R.; Griffiths, A.D.; Johnson, K.S.; Chiswell, D.J.; Hudson, P.; Winter, G. Multi-subunit proteins on the surface of filamentous phage: Methodologies for displaying antibody (Fab) heavy and light chains. Nucleic Acid Res., 1991, 19, 4133-7
135. Marks, J.D.; Hoogenboom, H.R.; Bonnert, T.P.; McCafferty, J.; Griffiths, A.D.; Winter, G. By-passing immunization: Human antibodies from V-gene libraries displayed on phage. J. Mol. Biol., 1991, 222, 581-97.
136. Dueñas, M.; Borrebaeck, C.A. Clonal selection and amplification of phage displayed antibodies by linking antigen recognition and phage replication. Biotechnology (N Y), 1994, 12, 999-1002.
137. Hawkins, R.E.; Russell, S.J.; Winter, G. Selection of phage antibodies by binding affinity. Mimicking affinity maturation. J. Mol. Biol. 1992, 226, 889-96.
138. Spada, S.; Krebber, C.; Pluckthun, A. Selectively infective phages (SIP). Biol. Chem., 1997, 378, 445-56.
139. Landon, L.A.; Deutscher, S.L. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell Biochem., 2003, 90, 509-17.
140. Newton, J.; Deutscher, S.L. Phage Peptide display. Handb. Exp. Pharmacol., 2008, 185, 145-63.
141. McCafferty, J. In: Phage Display of Peptides and Proteins; Brian K. Kay; John Winter; John McCafferty, Eds.; Academic Press Inc: San Diego, CA, USA, 1996; pp. 261-76.
142. Rondot, S.; Koch, J.; Breitling, F.; Dübel, S. A helper phage to improve single-chain antibody presentation in phage display. Nat. Biotechnol., 2001, 19, 75-8.
143. Baek, H.; Suk, K.H.; Kim, Y.H.; Cha, S. An improved helper phage system for efficient isolation of specific antibody molecules in phage display. Nucleic Acids Res., 2002, 30, e18.
144. Soltes, G.; Hust, M.; Ng, K.K.K.; Bansal, A.; Field, J.; Stewart, D.I.H.; Dubel, S.; Cha, S.; Wiersma, E.J. On the influence of vector design on antibody phage display. J. Biotechnol., 2007, 127, 626-637.
145. Hust, M.; Dubel, S. Phage display vectors for the in vitro generation of human antibody fragments. Methods Mol. Biol., 2005, 295, 71-96.
146. Mattheakis, L.C.; Bhatt, R.R.; Dower, W.J. An in vitro polysome display system for identifying ligands from very large peptide libraries. Proc. Natl. Acad. Sci. USA, 1994, 91, 9022-6.
147. Hanes, J.; Plückthun, A. In vitro selection and evolution of functional proteins by using ribosome display. Proc. Natl. Acad. Sci. USA, 1997, 94, 4937-42.
148. Hanes, J.; Jermutus, L.; Weber-Bornhauser, S.; Bosshard, H.R.; Pluckthun, A. Ribosome display efficiently selects and evolves high-affinity antibodies in vitro from immune libraries. Proc. Natl. Acad. Sci. USA, 1998, 95, 14130-5.
149. He, M.; Taussig, M.J. Antibodyribosome-mRNA (ARM) complexes as efficient selection particles for in vitro display and evolution of antibody combining sites. Nucleic Acids Res., 1997, 25, 5132-4.
150. Hanes, J.; Jermutus, L.; Schaffitzel, C.; Pluckthun, A. Comparison of Escherichia coli and rabbit reticulocyte ribosome display systems. FEBS Lett., 1999, 450, 105-10.
151. Roberts, R.W.; Szostak, J.W. RNA-peptide fusions for the in vitro selection of peptides and proteins. Proc. Natl. Acad. Sci. USA, 1997, 94, 12297-302.
152. Hanes, J.; Schaffitzel, C.; Knappik, A.; Pluckthun, A. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat. Biotechnol., 2000, 18, 1287-92.
153. Rothe, A.; Hosse, R.J.; Power, B.E. In vitro display technologies reveal novel Biopharmaceutics. FASEB J., 2006, 20, 1599-610.
154. Schmidt, F.R. Recombinant expression systems in the pharmaceutical industry. Appl. Microbiol. Biotechnol., 2004, 65, 363-72.
155. Proba, K.; Worn, A.; Honegger, A.; Pluckthun, A. Antibody scFv fragments without disulfide bonds made by molecular evolution. J. Mol. Biol., 1998, 275, 245-53.
156. Ge, L.; Knappik, A.; Pack, P.; Freund, C.; Plückthun, A. Antibody Engineering, Borrebaeck, C.A.K., Ed.; Oxford University Press: New York, 1995.
157. Sletta, H.; Tondervik, A.; Hakvag, S.; Aune, T.E.; Nedal, A.; Aune, R.; Evensen, G.; Valla, S.; Ellingsen, T.E.; Brautaset, T. The presence of N-terminal secretion signal sequences leads to strong stimulation of the total expression levels of three tested medically important proteins during high-cell-density cultivations of Escherichia coli. Appl. Environ. Microbiol., 2007, 73, 906-12.
158. Tachibana, H.; Takekoshi, M.; Cheng, X.J.; Nakata, Y.; Takeuchi, T.; Ihara, S. Bacterial expression of a human monoclonal antibodyalkaline phosphatase conjugate specific for Entamoeba histolytica. Clin. Diagn. Lab. Immunol., 2004, 11, 216-8.
159. Rusch, S.L.; Kendall, D.A. Interactions that drive Sec-dependent bacterial protein transport. Biochemistry, 2007, 46, 9665-73.
160. Thie, H.; Schirrmann, T.; Paschke, M.; Dubel, S.; Hust, M. SRP and Sec pathway leader peptides for antibody phage display and antibody fragment production in E. coli. New Biotechnol., 2008, 25, 49-54.
161. Levy, R.; Weiss, R.; Chen, G.; Iverson B.L.; Georgiou G. Production of correctly folded Fab antibody fragment in the cytoplasm of Escherichia coli trxB gor mutants via the coexpression of molecular chaperones. Protein Expr. Purif., 2001, 23, 338-47
162. Jordan, E.; Hust, M.; Roth, A.; Biedendieck, R.; Schirrmann, T.; Jahn D.; Dübel, S. Production of recombinant antibody fragments in Bacillus megaterium. Microb. Cell Fact., 2007, 6, 2-13.
163. Shiroza, T.; Shinozaki-Kuwahara, N.; Hayakawa, M.; Shibata, Y.; Hashizume, T.; Udaka, S.; Abiko, Y. Production of a single-chain variable fraction capable of inhibiting the Streptococcus mutans glucosyltransferase in Bacillus brevis: Construction of a chimeric shuttle plasmid secreting its gene product. BBA, 2003, 1626, 57-64.
164. Wu, S.C.; Ye, R.; Wu, X.C.; Ng, S.C.; Wong, S.L. Enhanced secretory production of a single-chain antibody fragment from Bacillus subtilis by coproduction of molecular chaperons. J. Bacteriol. 1998, 180, 2830-5.
165. Li, H.; Sethuraman, N.; Stadheim, T.A.; Zha, D.; Prinz, B.; Ballew, N.; Bobrowicz, P.; Choi, B.; Cook, W.J.; Cukan, M.; Houston-Cummings, N.R.; Davidson, R.; Gong, B.; Hamilton, S.R.; Hoopes, J.P.; Jiang, Y.; Kim, N.; Mansfield, R.; Nett, J.H.; Rios, S.; Strawbridge, R.; Wildt, S.; Gerngross, T.U. Optimization of humanized IgGs in glycoengineered Pichia pastoris. Nat. Biotechnol., 2006, 24, 210-5.
166. Schirrmann, T.; Al-Halabi, L.; Dübel, S.; Hust, M. Production systems for recombinant antibodies. Front. Biosci., 2008, 13, 4576-94.
167. Chiarella, P.; Fazio, V.M. Mouse monoclonal antibodies in biological research: Strategies for high-throughput production. Biotechnol. Lett., 2008, 30, 1303-10.
168. Nimmerjahn, F.; Ravetch, J.V. Antibodies, Fc receptors and cancer. Curr Opin Immunol. 2007, 19, 239-45.
169. Coiffier, B. Rituximab therapy in malignant lymphoma. Oncogene, 2007, 26, 3603-13.
170. Hudis, C.A. Trastuzumab-mechanism of action and use in clinical practice. N. Engl. J. Med., 2007, 357, 39-51.
171. Mone, A.P.; Cheney, C.; Banks, A.L.; Tridandapani, S.; Mehter, N.; Guster, S.; Lin, T.; Eisenbeis, C.F.; Young, D.C.; Byrd, J.C. Alemtuzumab induces caspase-independent cell death in human chronic
172. Sibéril, S.; Dutertre, C.A.; Fridman, W.H.; Teillaud, J.L. FcgammaR: The key to optimize therapeutic antibodies? Crit. Rev. Oncol. Hematol., 2007, 6226-33.
173. Shen, J.; Zhu, Z. Catumaxomab, a rat/murine hybrid trifunctional bispecific monoclonal antibody for the treatment of cancer. Curr. Opin. Mol. Ther., 2008, 10, 273-84.
174. Sebastian, M.; Passlick, B.; Friccius-Quecke, H.; Jeger, M.; Lindhofer, H.; Kanniess, F.; Wiewrodt, R.; Thiel, E.; Buhl, R.; Schmittel, A. Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): A phase I study. Cancer Immunol. Immunother., 2007, 56, 1637-44.
175. Bonavida, B. Rituximab-induced inhibition of antiapoptotic cell survival pathways: Implications in chemo/immunoresistance, rituximab unresponsiveness, prognostic and novel therapeutic interventions. Oncogene, 2007, 26, 3629-36.
176. Shields, R.L.; Namenuk, A.K.; Hong, K.; Meng, Y.G.; Rae, J.; Briggs, J.; Xie, D.; Lai, J.; Stadlen, A.; Li, B.; Fox, J.A.; Presta, L.G. High resolution mapping of the binding site on human IgG1 for FcγRI, FcγRII, FcγRIII and FcRn and design of IgG1 variants with improved binding for the FcγR. J. Biol. Chem., 2000, 276, 6591-604.
177. Lens, M.; Ferrucci, P.F.; Testori, A. Anti-CTLA4 monoclonal antibody ipilimumab in the treatment of metastatic melanoma: Recent findings. Recent Patents Anticancer Drug Discov., 2008, 3, 105-13.
178. Kontermann, R.E.; Wing, M.G.; Winter, G. Complement recruitment using bispecific diabodies. Nature Biotechnol., 1997, 15, 629-31.
179. Kipriyanov, S.M.; Cochlovius, B.; Schafer, H.J.; Moldenhauer, G.; Bähre, A.; Le Gall, F.; Knackmuss, S.; Little, M. Synergistic antitumor effect of bispecific CD19 x CD3 and CD19 x CD16 diabodies in a preclinical model of non Hodgkin's Iymphoma. J. lmmunol., 2002, 169, 137-44.
180. Holliger, P.; Brissinck, J.; Williams, R.L.; Thielemans, K.; Winter, G. Specific killing of lymphoma cells by cytotoxic T-cells mediated by a bispecific diabody. Protein Eng., 1996, 9, 299-305
181. Cochlovius, B.; Kipriyanov, S.M.; Stassar, M.J.; Christ, O.; Schuhmacher, J.; Strass, G.; Moldenhauer, G.; Little, M. Treatment of human B cell lymphoma xenografts with a CD3 x CD19 diabody and T cells. J. Immunol., 2000, 165, 888-95.
182. Peipp, M.; Valerius, T. Bispecific antibodies targeting cancer cells. Biochem. Soc. Trans., 2002, 30, 507-11.
183. Wolf, E.; Hofmeister, R.; Kufer, P.; Schlereth, B.; Baeuerle, P.A. BiTEs: Bispecific antibody constructs with unique anti-tumor activity. Drug Discov. Today, 2005, 10, 1237-449.
184. www.clinicalTrials.gov NCT00274742, Safety Study to Investigate the bispecific T-cell Engager MT103 in patients with relapsed NonHodgkin's Lymphoma.
185. www.clinicalTrials.gov NCT00560794, Phase II Study of the BiTE® MT-103 in patients with minimal residual disease of B-precursor acute ALL.
186. www.clinicalTrials.gov CT00635596 Study of MT110-101 in Colorectal Cancer (CRC); Gastrointestinal (GI) and Lung Cancer.
187. Lunde, E.; Lauvrak, V.; Rasmussen, I.B.; Schjetne, K.W.; Thompson, K.M.; Michaelsen, T.E.; Brekke, O.H.; Sollid, L.M.; Bogen, B.; Sandlie, I. Troybodies and Pepbodies. Biochem. Soc. Trans., 2002, 30, 500-6.
188. Beckman, R.A.; Weiner, L.M.; Davis, H.M. Antibody constructs in cancer therapy: Protein engineering strategies to improve exposure in solid tumors. Cancer, 2007, 109, 170-9.
189. Li, B.; Shi, S.; Qian, W.; Zhao, L.; Zhang, D.; Hou, S.; Zheng, L.; Dai, J.; Zhao, J.; Wang, H.; Guo, Y. Development of novel tetravalent anti-CD20 antibodies with potent antitumor activity. Cancer Res., 2008, 68, 2400-8.
190. Camidge, D.R. Apomab: An agonist monoclonal antibody directed against Death Receptor 5/TRAIL-Receptor 2 for use in the treatment of solid tumors. Expert. Opin. Biol. Ther., 2008, 8, 1167-76
191. Hotte, S.J.; Hirte, H.W.; Chen, E.X.; Siu, L.L.; Le, L.H.; Corey, A.; Iacobucci, A.; MacLean, M.; Lo, L.; Fox, N.L.; Oza, A.M. A phase 1 study of mapatumumab (fully human monoclonal antibody to TRAIL-R1) in patients with advanced solid malignancies. Clin. Cancer Res., 2008, 14, 3450-5.
192. Greco, F.A.; Bonomi, P.; Crawford, J.; Kelly, K.; Oh, Y.; Halpern, W.; Lo, L.; Gallant, G.; Klein, J. Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer. Lung Cancer, 2008, 61, 82-90.
193. Lacy, S.E.; DeVries, P.J.; Xie, N.; Fung, E.; Lesniewski, R.R.; Reilly, E.B. The potency of erythropoietin-mimic antibodies correlates inversely with affinity. J. Immunol., 2008, 181, 1282-7.
194. Rajeshwari, K.; Karande, A.A. Molecular mimicry by antiidiotypic monoclonal antibody to gonadotropin releasing hormone. Immunol. Invest., 1999, 28, 103-14.
195. Goletz, S.; Christensen, P.A.; Kristensen, P.; Blohm, D.; Tomlinson, I.; Winter, G.; Karsten, U. Selection of large diversities of antiidiotypic antibody fragments by phage display. J. Mol. Biol., 2002, 315, 1087-97.
196. www.clinical trials.gov NCT00003279. Vaccination Therapy in Treating Patients With Limited-Stage Small Cell Lung Cancer.
197. www.clinical trials.gov NCT00006352. Monoclonal Antibody Therapy Plus BCG in Treating Patients With Limited-Stage Small Cell Lung Cancer.
198. Hommes, D.W.; Mikhajlova, T.L.; Stoinov, S.; Stimac, D.; Vucelic, B.; Lonovics, J.; Zákuciova, M.; D'Haens, G.; Van Assche, G.; Ba, S.; Lee, S.; Pearce, T. Fontolizumab, a humanised antiinterferon gamma antibody, demonstrates safety and clinical activity in patients with moderate to severe Crohn's disease. Gut, 2006, 55, 1131-7.
199. Mejías, A.; Chávez-Bueno, S.; Raynor, M.B.; Connolly, J.; Kiener, P.A.; Jafri, H.S.; Ramilo, O. Motavizumab, a neutralizing antiRespiratory Syncytial Virus (Rsv) monoclonal antibody significantly modifies the local and systemic cytokine responses induced by Rsv in the mouse model. Virol. J., 2007, 4, 109.
200. Choudhry, V.; Zhang, M.Y.; Dimitrova, D.; Prabakaran, P.; Dimitrov, A.S.; Fouts, T.R.; Dimitrov, D.S. Antibody-based inhibitors of HIV infection. Expert Opin. Biol. Ther., 2006, 6, 523-31.
201. Huber, M.; Olson, W.C.; Trkola, A. Antibodies for HIV treatment and prevention: Window of opportunity? Curr. Top. Microbiol. Immunol., 2008, 317, 39-66.
202. Bregenholt, S.; Jensen, A.; Lantto, J.; Hyldig, S.; Haurum, J.S. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Curr. Pharm. Des., 2006, 12, 2007-15.
203. Marasco, W.A.; Sui, J. The growth and potential of human antiviral monoclonal antibody therapeutics. Nat. Biotechnol., 2007, 25, 1421-34.
204. de Kruif, J.; Bakker, A.B.; Marissen, W.E.; Kramer, R.A.; Throsby, M.; Rupprecht, C.E.; Goudsmit, J. A human monoclonal antibody cocktail as a novel component of rabies postexposure prophylaxis. Annu Rev. Med., 2007, 58, 359-68.
205. Gish, R.G.; McCashland, T. Hepatitis B in liver transplant recipients. Liver Transpl., 2006, 12, 54-64.
206. Lang, A.B.; Cryz, S.J. Jr.; Schurch, U.; Ganss M.T.; Bruderer, U. Immunotherapy with human monoclonal antibodies. Fragment A specificity of polyclonal and monoclonal antibodies is crucial for full protection against tetanus toxin. J. Immunol., 1993, 151, 466-72.
207. Mukherjee, J.; Chios, K.; Fishwild, D.; Hudson, D.; O'Donnell, S.; Rich, S.M.; Donohue-Rolfe, A.; Tzipori, S. Production and characterization of protective human antibodies against shiga toxin 1. Infect. Immunol., 2002, 70, 5896-9.
208. Semenza G.L. A new weapon for attacking tumor blood vessels. New Engl. J. Med., 2008, 358, 2066-7.
209. Eremina, V.; Jefferson, J.A.; Kowalewska, J.; Hochster, H.; Haas, M.; Weisstuch, J.; Richardson, C.; Kopp, J.B.; Kabir, M.G.; Backx, P.H.; Gerber, H.P.; Ferrara, N.; Barisoni, L.; Alpers, C.E.; Quaggin, S.E. VEGF inhibition and renal thrombotic microangiopathy. N. Engl. J. Med., 2008, 358, 1129-36.
210. Velcheti, V.; Viswanathan, A.; Govindan, R. The proportion of patients with metastatic non-small cell lung cancer potentially eligible for treatment with Bevacizumab: A single institutional survey. J. Thoracic Oncol., 2006, 1, 501.
211. Azad, R.; Chandra, P. Intravitreal bevacizumab in aggressive posterior retinopathy of prematurity. Indian J. Ophthalmol., 2007, 55, 319.
212. Schrama, D.; Reisfeld, R.A.; Becker, J.C. Antibody targeted drugs as cancer therapeutics. Nat. Rev. Drug Discov., 2006, 5, 147-59.
213. Bagshawe, K.D.; Sharma, S.K.; Begent, R.H. Antibody-directed enzyme prodrug therapy (ADEPT) for cancer. Expert Opin. Biol. Ther., 2004, 4, 1777-8.
214. McEarchern, J.A.; Oflazoglu, E.; Francisco, L.; McDonagh, C.F.; Gordon, K.A.; Stone, I.; Klussman, K.; Turcott, E.; Rooijen, N.; Carter, P.; Grewal, I.S.; Wahl, A.F.; Law C.L. Engineered antiCD70 antibody with multiple effector functions exhibits in vitro and in vivo antitumor activities. Blood, 2007, 109, 1185-92.
215. Larson, R.A.; Boogaerts, M.; Estey, E.; Karanes, C.; Stadtmauer, E.A.; Sievers, E.L.; Mineur, P.; Bennett, J.M.; Berger, M.S.; Eten, C.B.; Munteanu, M.; Loken, M.R.; Van Dongen, J.J.; Bernstein, I.D.; Appelbaum, F.R.; Mylotarg Study Group. Antibody-targeted chemotherapy of older patients with acute myeloid leukemia in first relapse using Mylotarg (gemtuzumab ozogamicin). Leukemia, 2002, 16, 1627-36.
216. Chari, R.V.J. Targeted cancer therapy: Conferring specificity to cytotoxic drugs. Acc. Chem. Res., 2008, 41, 98-107
217. Rybak, S.M.; Newton, D.L. In Handbook of Therapeutic Antibodies; Stefan Dübel, Ed.; Weinheim, Germany: Wiley-VCH, 2007; Vol. 1, pp. 379-410.
218. Wu, Y.; Mikulski, S.M.; Ardelt, W.; Rybak, S.M.; Youle, R.J. A cytotoxic ribonuclease: Study of the mechanism of onconase cytotoxicity. J. Biol. Chem., 1993; 268, 10686-93.
219. Rybak, S.M.; Saxena, S.K.; Ackerman, E.J.; Youle, R.J. Cytotoxic potential of ribonuclease and ribonuclease hybrid proteins. J. Biol. Chem., 1991, 266, 21202-7.
220. Zewe, M.; Rybak, S.M.; Dübel, S.; Coy, J.F.; Welschof, M.; Newton, D.L.; Little, M. Cloning and cytotoxicity of a human pancreatic RNase immunofusion. Immunotechnology, 1997, 3, 127-36.
221. Dübel, S. Reconstitution of human RNase A from two separate fragments fused to different single chain antibody fragments: On the way to binary immunotoxins. Tumor Targeting, 1999, 4, 37-46.
222. De Lorenzo, C.; Di Malta, C.; Cali, G.; Troise, F.; Nitsch, L.; D'Alessio, G. Intracellular route and mechanism of action of ERBhRNase, a human anti-ErbB2 anticancer immunoagent. FEBS Lett., 2007, 581, 296-300.
223. Arndt, M.A.; Krauss, J.; Vu, B.K.; Newton, D.L.; Rybak, S.M. A dimeric angiogenin immunofusion protein mediates selective toxicity toward CD22+ tumor cells. J. Immunother., 2005, 28, 245-51.
224. De Lorenzo, C.; Arciello, A.; Cozzolino, R.; Palmer, D.B.; Laccetti, P.; Piccoli, R.; D'Alessio G. A fully human antitumor immunoRNase selective for ErbB-2-positive carcinomas. Cancer Res., 2004, 64, 4870-4.
225. Menzel, C.; Schirrmann, T.; Konthur, Z.; Jostock, T.; Dübel S. Human antibody RNase fusion protein targeting CD30+ lymphomas. Blood, 2008, 111, 3830-37.
226. Rosenberg, S.A.; Yang, J.C.; White, D.E.; Steinberg, S.M. Durability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: Identification of the antigens mediating response. Ann. Surg., 1998, 228, 307-19.
227. Ruef, C.; Coleman, D.L. Granulocyte-macrophage colony-stimulating factor: Pleiotropic cytokine with potential clinical usefulness. Rev. Infect. Dis., 1990, 12, 41-62.
228. Tsung, K.; Meko, J.B.; Peplinski, G.R.; Tsung, Y.L.; Norton, J.A. IL-12 induces T helper 1-directed antitumor response. J. Immunol., 1997, 158, 3359-65.
229. Cohen, J. Clinical trials - IL-12 deaths - Explanation and a puzzle. Science, 1995, 270, 908.
230. Maas, R.A.; Dullens, H.F.; Den Otter, W. Interleukin-2 in cancer treatment: Disappointing or (still) promising? A review. Cancer Immunol. Immunother., 1993, 36, 141-8.
231. Siegel, J.P.; Puri, R.K. Interleukin-2 toxicity. J. Clin. Oncol., 1991, 9, 694-704.
232. Ortiz-Sánchez, E.; Helguera, G.; Daniels, T.R.; Penichet, M.L. Antibody-cytokine fusion proteins: Applications in cancer therapy. Expert Opin. Biol. Ther., 2008, 8, 609-32.
233. Lunde, E.; Munthe, L.; Vabø, A.; Sandlie, I.; Bogen, B. Antibodies engineered with IgD specificity efficiently deliver integrated T cell epitopes for antigen presentation by B cells. Nat. Biotechnol., 1999, 17, 670-5.
234. Lunde, E.; Western, K.H.; Rasmussen, I.B.; Sandlie, I.; Bogen, B. Efficient delivery of T cell epitopes to APC by use of MHC class II-specific Troybodies. J. Immunol., 2002, 168, 2154-62.
235. Tunheim, G.; Schjetne, K.W.; Fredriksen, A.B.; Sandlie, I.; Bogen, B. Human CD14 is an efficient target for recombinant immunoglobulin vaccine constructs that deliver T cell epitopes. J. Leukoc. Biol., 2005, 77, 303-10.
236. Tunheim, G.; Thompson, K.M.; Fredriksen, A.B.; Espevik, T.; Schjetne, K.W.; Bogen, B. Human receptors of innate immunity (CD14, TLR2) are promising targets for novel recombinant immunoglobulin-based vaccine candidates. Vaccine, 2007, 25, 4723-34.
237. Heng, B.C.; Cao, T. Making cell-permeable antibodies (Transbody) through fusion of protein transduction domains (PTD) with single chain variable fragment (scFv) antibodies: Potential advantages over antibodies expressed within the intracellular environment (Intrabody). Med. Hypotheses, 2005, 64, 1105-8.
238. Muller, S.; Zhao, Y.; Brown, T.L.; Morgan, A.C.; Kohler, H. TransMabs: cell-penetrating antibodies, the next generation. Expert Opin. Biol. Ther., 2005, 5, 237-41.
239. Williams, B.R.; Zhu, Z. Intrabody-based approaches to cancer therapy: status and prospects. Curr. Med. Chem., 2006, 13, 1473-80.
240. Cardinale, A.; Biocca, S. Combating protein misfolding and aggregation by intracellular antibodies. Curr. Mol. Med., 2008, 8, 2-11.
241. Doorbar, J.; Griffin, H. Intrabody strategies for the treatment of human papillomavirus-associated disease. Expert Opin. Biol. Ther., 2007, 7, 677-89.
242. Paul, S.; Nishiyama, Y.; Planque, S.; Karle, S.; Taguchi, H.; Hanson, C.; Weksler, M.E. Antibodies as defensive enzymes. Springer Semin. Immunopathol., 2005, 26, 485-503.
243. Planque, S.; Bangale, Y.; Song, X.T.; Karle, S.; Taguchi, H.; Poindexter, B.; Bick, R.; Edmundson, A.; Nishiyama, Y.; Paul, S. Ontogeny of proteolytic immunity: IgM serine proteases. J. Biol. Chem., 2004, 279, 14024-32.
244. Planque, S.; Taguchi, H.; Burr, G.; Bhatia, G.; Karle, S.; Zhou, Y.X.; Nishiyama, Y.; Paul, S. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J. Biol. Chem., 2003, 278, 20436-43.
245. Gololobov, G.; Sun, M.; Paul, S. Innate antibody catalysis. Mol. Immunol., 1999, 36, 1215-22.
246. Hifumi, E.; Mitsuda, Y.; Ohara, K.; Uda, T. Targeted destruction of the HIV-1 coat protein gp41 by a catalytic antibody light chain. J. Immunol. Methods, 2002, 269, 283-98.
247. Mitsuda, Y.; Hifumi, E.; Tsuruhata, K.; Fujinami, H.; Yamamoto, N.; Uda, T. Catalytic antibody light chain capable of cleaving a chemokine receptor CCR-5 peptide with a high reaction rate constant. Biotechnol. Bioeng., 2004, 86, 217-25.
248. Kalaga, R.; Li, L.; O'fDell, J.R.; Paul, S. Unexpected presence of polyreactive catalytic antibodies in IgG from unimmunized donors and decreased levels in rheumatoid arthritis. J. Immunol., 1995, 155, 2695-702.
249. Lacroix-Desmazes, S.; Bayry J.; Kaveri S.V.; Hayon-Sonsino, D.; Thorenoor N.; Charpentier J.; Luyt, C.E.; Mira, J.P.; Nagaraja, V.; Kazatchkine, M.D. High levels of catalytic antibodies correlate with favorable outcome in sepsis. Proc. Natl. Acad. Sci. USA, 2005, 102, 4109-13.
250. Nieva, J.; Wentworth, P. Jr. The antibody-catalyzed water oxidation pathway - a new chemical arm to immune defense? Trends Biochem. Sci., 2004, 29, 274-8.
251. Tanaka, F. Catalytic antibodies as designer proteases and esterases. Chem. Rev., 2002, 102, 4885-906.
252. Paul, S.; Karle, S.; Planque, S.; Taguchi, H.; Salas, M.; Nishiyama, Y.; Handy, B.; Hunter, R.; Edmundson, A.; Hanson, C. Naturally occurring proteolytic antibodies: Selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J. Biol. Chem., 2004, 279, 39611-9.
253. Matsuura, K.; Ikoma, S.; Sugiyama, M.; Funauchi, M.; Sinohara, H. Amidolytic and peptidolytic activities of immunoglobulin G present in sera from patients with rheumatoid arthritis, Sjogren's syndrome and systemic lupus erythematosus. Immunology, 1998, 95, 26-30.
254. Nevinsky, G.A.; Buneva, V.N. Catalytic antibodies in healthy humans and patients with autoimmune and viral diseases. J. Cell Mol. Med., 2003, 7, 265-76.
255. Bangale, Y.; Karle, S.; Planque, S.; Zhou, Y.X.; Taguchi, H.; Nishiyama, Y.; Li, L.; Kalaga, R.; Paul, S. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J., 2003, 17, 628-35.
256. Voice, J.K.; Grinninger, C.; Kong, Y.; Bangale, Y.; Paul, S.; Goetzl, E.J. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wild-type mice and T cell-targeted type II VIP receptor transgenic mice. J. Immunol., 2003, 170, 308-14.
257. Gololobov, G.V.; Rumbley, C.A.; Rumbley, J.N.; Schourov, D.V.; Makarevich, O.I.; Gabibov, A.G.; Voss, E.W. Jr; Rodkey, L.S. DNA hydrolysis by monoclonal anti-ssDNA autoantibody BV 04-01: Origins of catalytic activity. Mol. Immunol., 1997, 34, 1083-93.
258. Tanaka, F.; Barbas, C.F. 3rd. Reactive immunization: A unique approach to catalytic antibodies. J. Immunol. Methods, 2002, 269, 67-79.
259. Soumillion, P.; Fastrez J. Novel concepts for selection of catalytic activity. Curr. Opin. Biotechnol., 2001, 12, 387-394.
260. Deng, S.X.; de Prada, P.; Landry, D.W. Anticocaine catalytic antibodies. J. Immunol. Methods, 2002, 269, 299-310.
261. Briscoe, R.J.; Jeanville, P.M.; Cabrera, C.; Baird, T.J.; Woods, J.H.; Landry, D.W. A catalytic antibody against cocaine attenuates cocaine's cardiovascular effects in mice: A dose and time course analysis. Int. Immunopharmacol., 2001, 1, 1189-98.
262. Mets, B.; Winger, G.; Cabrera, C.; Seo, S.; Jamdar, S.; Yang, G.; Zhao, K.; Briscoe, R.J.; Almonte, R.; Woods, J.H.; Landry, D. W. A catalytic antibody against cocaine prevents cocaine's reinforcing and toxic effects in rats. Proc. Natl. Acad. Sci. USA, 1998, 95, 10176-81.
263. Homayoun, P.; Mandal, T.; Landry, D.; Komiskey, H. Controlled release of anti-cocaine catalytic antibody from biodegradable polymer microspheres. J. Pharm. Pharmacol., 2003, 55, 933-8.
264. Dickerson, T.J.; Yamamoto, N.; Janda, K.D. Antibody-catalyzed oxidative degradation of nicotine using riboflavin. Bioorg. Med. Chem., 2004, 12, 4981-7.
265. Sun, Y.; Mu, Y.; Li, W.; Lv, S.; Jiang, Z.; Zhang, K.; Zheng, K.; Lin, F.; Yan, G.; Luo, G. Protection of epidermal cells against UVB injury by the antioxidant selenium-containing single-chain Fv catalytic antibody. Arch. Biochem. Biophys., 2003, 412, 90-4.
266. Powers, J.C.; Asgian, J.L.; Ekici, O.D.; James, K.E. Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev., 2002, 102, 4639-750.
267. Paul, S.; Planque, S.; Zhou, Y.X.; Taguchi, H.; Bhatia, G.; Karle, S.; Hanson, C.; Nishiyama, Y. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J. Biol. Chem., 2003, 278, 20429-35.
268. Karle, S.; Planque, S.; Nishiyama, Y.; Taguchi, H.; Zhou, Y.X.; Salas, M.; Lake, D.; Thiagarajan, P.; Arnett, F.; Hanson, C.V.; Paul, S. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS, 2004, 18, 329-31.
269. Mitsuda, Y.; Tsuruhata, K.; Hifumi, E.; Takagi, M.; Uda, T. Investigation of active form of catalytic antibody light chain 41S-2-L. Immunol. Lett., 2005, 96, 63-71.
270. Lehner, T. The role of CCR5 chemokine ligands and antibodies to CCR5 coreceptors in preventing HIV infection. Trends Immunol., 2002, 23, 347-51.
271. Rangan, S.K.; Liu, R.; Brune, D.; Planque, S.; Paul, S.; Sierks, M.R. Degradation of beta-amyloid by proteolytic antibody light chains. Biochemistry, 2003, 42, 14328-34.
272. Taguchi, H.; Planque, S.; Nishiyama, Y.; Szabo, P.; Weksler, M.E.; Friedland, R.P.; Sudhir, P. Catalytic antibodies to amyloid β peptide in defense against Alzheimer disease. Autoimmun. Rev., 2008, 7, 391-7.
273. Weksler, M.E.; Relkin, N.; Turkenich, R.; LaRusse, S.; Zhou, L.; Szabo, P. Patients with Alzheimer disease have lower levels of serum anti-amyloid peptide antibodies than healthy elderly individuals. Exp. Gerontol., 2002, 37, 943-8.
274. Liu, R.; McAllister, C.; Lyubchenko, Y.; Sierks, M.R. Proteolytic antibody light chains alter beta-amyloid aggregation and prevent cytotoxicity. Biochemistry, 2004, 43, 9999-10007.
275. Nishi, Y. Enzyme/abzyme prodrug activation systems: Potential use in clinical oncology. Curr. Pharm. Des., 2003, 9, 2113-30.
276. Jones, L.H.; Wentworth, P. Jr. The therapeutic potential for catalytic antibodies: From a concept to a promise. Med. Chem., 2001, 1, 125-32.
277. Pessah, N.; Reznik, M.; Shamis, M.; Yantiri, F.; Xin, H.; Bowdish, K.; Shomron, N.; Ast, G.; Shabat, D. Bioactivation of carbamatebased 20(S)-camptothecin prodrugs. Bioorg. Med. Chem., 2004, 12, 1859-66.
278. Shamis, M.; Lode, H.N.; Shabat, D. Bioactivation of self-immolative dendritic prodrugs by catalytic antibody 38C2. J. Am. Chem. Soc., 2004, 126, 1726-31.
279. Sinha, S.C.; Li, L.S.; Miller, G.P.; Dutta, S.; Rader, C.; Lerner, R.A. Prodrugs of dynemicin analogs for selective chemotherapy mediated by an aldolase catalytic Ab. Proc. Natl. Acad. Sci. USA, 2004, 101, 3095-9.
280. Briggs, G.E.; Haldane, J.B.S. A note on the kinetics of enzyme action. Biochem. J., 1925, 19, 338-9.
281. Darvey, I.G.; Prokhovnik, S.J.; Williams, J.F. A new method for the derivation of rate equations in enzyme kinetics using the maximum rate of product formation. Biochim. Biophys. Acta, 1965, 110, 1-8.
282. Dixon, M. Graphical determination of equilibrium constants. Biochem. J., 1965, 94, 760-2.
283. Dixon, M. The graphical determination of Km and Ki. Biochem. J., 1972, 129, 197-202.
284. Benkovic, S.J. The key is in the pocket. Nature, 1996, 383, 23-4.
285. Jacobs, J.W. New perspective on catalytic antibodies. Biotechnology, 1991, 9, 258-62.
286. Frenzen, C.L.; Maini, P.K. Enzyme kinetics for a two-step enzymic reaction with comparable initial enzyme-substrate ratios. J. Math. Biol., 1988, 26, 689-703.
287. Varòn, R.; Ruiz-Galea, M.M.; Garrido-del Solo, C.; Garcìa-Sevilla, F.; Garcìa-Moreno, M.; Garcìa-Cànovas, F.; Havsteen, B.H. Transient phase of enzyme reactions. Time course equations of the strict and the rapid equilibrium conditions and their computerized derivation. Biosystems, 1999, 50, 99-126.
288. Michaelis, L.; Menten, M.L. Die kinetik der Invertinwirkung. Biochem. Z., 1913, 49, 333-69.
289. Dixon, M.; Webb, E.C. In Enzymes 3rd edition; Longman: London, 1979; pp. 124-6.
290. Toti, P.; Petri, A.; Pelaia, V.; Osman, A.M.; Paolini, M.; Bauer, C. A linearization method for low catalytic activity enzyme kinetic analysis. Biophys. Chem., 2005, 114, 245-51.
291. Chari, R.V.J. Targeted delivery of chemotherapeutics: Tumor-activated prodrug therapy. Adv. Drug Deliv. Rev., 1998, 31, 89-104.
292. Nosari, A.; Tedeschi, A.; Ricci, F.; Montillo, M. Characteristics and stage of the underlying diseases could determine the risk of opportunistic infections in patients receiving alemtuzumab. Haematologica, 2007, 92, 784-94.
293. Silverman, G.J.; Boyle, D.L. Understanding the mechanistic basis in rheumatoid arthritis for clinical response to anti-CD20 therapy: The B-cell roadblock hypothesis. Immunol. Rev., 2008, 223, 175-85.
294. Plosker, G.L.; Figgitt, D.P. Rituximab: A review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia. Drugs, 2003, 63, 803-43.
295. Goldblatt, F.; Isenberg, D.A. Anti-CD20 monoclonal antibody in rheumatoid arthritis and systemic lupus erythematosus. Handb. Exp. Pharmacol., 2008, 181, 163-81.
296. Lorenz, H.M. T-cell-activation inhibitors in rheumatoid arthritis. BioDrugs, 2003, 17, 263-70.
297. Pries, A.R.; Kuebler, W.M. Normal endothelium. Handb. Exp. Pharmacol., 2006, 176, 1-40.
298. Xu, H.; Dawson, R.; Crane, I.J.; Liversidge, J. Leukocyte diapedesis in vivo induces transient loss of tight junction protein at the blood-retina barrier. Invest. Ophthalmol. Vis. Sci., 2005, 46, 2487-94.
299. Willis, C.L.; Leach, L.; Clarke, G.J.; Nolan, C.C.; Ray, D.E. Reversible disruption of tight junction complexes in the rat blood-brain barrier, following transitory focal astrocyte loss. Glia, 2004, 48, 1-13.
300. Sedlacek, H.H.; Seemann, G.; Hoffmann, D.; Czech, J.; Lorenz, P.; Kolar, C.; Bosslet, K. In Contributions to Oncology; Karger: Basel, Switzerland, 1992; pp. 1-145.
301. Adams, G.P.; Schier, R.; McCall, A.M.; Simmons, H.H.; Horak, E.M.; Alpaugh, R.K.; Marks, J.D.; Weiner, L.M. High affinity restricts the localization and tumor penetration of single-chain fv antibody molecules. Cancer Res., 2001, 61, 4750-55.
302. Nielsen, U.B.; Adarns, G.P.; Weiner, L.M.; Marks J.D. Targeting of bivalent antl-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity. Cancer Res., 2000, 60, 6434-40.
303. Liu, X.Y.; Pop, L.M.; Vitetta, E.S. Engineering therapeutic monoclonal antibodies. Immunol. Rev., 2008, 222, 9-27.
304. Pop, L.M.; Liu, X.; Ghetie, V.; Vitetta, E.S. The generation of immunotoxins using chimeric anti-CD22 antibodies containing mutations which alter their serum half-life. Int. Immunopharmacol., 2005, 5, 1279-90.
305. Anderson, W.L.; Tomasi, T.B. Polymer modification of antibody to eliminate immune complex and Fc binding. J. Immunol. Methods, 1988, 109, 37-42.
306. Chapman, A.P. PEGylated antibodies and antibody fragments for improved therapy: A review. Adv. Drug Deliv. Rev., 2002, 54, 531-45.
307. Chapman, A.P.; Antoniw, P.; Spitali, M.; West, S.; Stephens, S.; King, D.J. Therapeutic antibody fragments with prolonged in vivo half-lives. Nat. Biotechnol., 1999, 17, 780-83.
308. King, D.J.; Turner, A.; Farnsworth, A.P.; Adair, J.R.; Owens, R.J.; Pedley, R.B.; Baldock, D.; Proudfoot, K.A.; Lawson, A.D.; Beeley, N.R.; et al. Improved tumor targeting with chemically cross-linked recombinant antibody fragments. Cancer Res., 1994, 54(23), 6176-85.
309. Tsutsumi, Y.; Onda, M.; Nagata, S.; Lee, B.; Kreitman, R.J.; Pastan, I. Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity. Proc. Natl. Acad. Sci. USA, 2000, 97(15), 8548-53.
310. Choy, E.H.; Hazleman, B.; Smith, M.; Moss, K.; Lisi, L.; Scott, D.G.; Patel, J.; Sopwith, M.; Isenberg, D.A. Efficacy of a novel PEGylated humanized anti-TNF fragment (CDP870) in patients with rheumatoid arthritis: A phase II double-blinded, randomized, dose-escalating trial. Rheumatology (Oxford), 2002, 41(10), 1133-7.
311. Lang, L. FDA approves Cimzia to treat Crohn's disease. Gastroenterology, 2008, 134, 1819.